WebThe plasmaMATCH study has provided further insights into mechanisms of fulvestrant resistance. 82 Cohort A of this study enrolled patients with ER positive advanced breast cancer with baseline... WebFeature. The Medical Clinical Trials database is the most comprehensive clinical trials database in the market. Benefit. Covers planned, ongoing, completed and terminated / suspended / withdrawn trials, and outlines information regarding trial type, study design, objective, end points, patient details, results, investigators, locations, contact details, and …
肿瘤药物临床试验设计之伞式试验_《中国胸心血管外科临床杂志 …
WebJan 10, 2024 · The plasmaMATCH Trial: A multiple parallel cohort, open-label, multi-centre phase-II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer... WebOct 1, 2024 · plasmaMATCH is a multicohort, open-label, non-randomised, phase 2a clinical trial platform run across 18 UK hospitals ( appendix p 2 ). Investigators at UK hospitals registered eligible patients with the Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) for ctDNA testing. buzz word game how to play
“plasmaMATCH” Trial Matches Female Breast Cancer Patients to …
WebApr 23, 2024 · The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical … WebFeb 5, 2024 · The study’s lead author,Nicholas Turner, PhD, MA, MRCP, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, both in London, England, said during the presentation that the plasmaMATCH trial was designed to assess the clinical utility of using ctDNA testing to select patients for targeted therapies. WebSep 17, 2024 · plasmaMATCH Platform Trial Finds ctDNA Effective for Patients with Breast Cancer. Sep 17, 2024. Hannah Slater. Results from the study suggest that ctDNA testing … cetronia health center